Ov Finance|Chrysler recalls 142,000 Ram vehicles: Here's which models are affected

2025-04-28 15:46:00source:Crypencategory:Scams

Chrysler is Ov Financerecalling over 142,000 vehicles of various makes and models for potential issues with high beam headlights and turn signals inadvertently turning on.

The recall is for certain 2023 Ram 1500 Classic, Ram 3500 Classic, 3500 Cab Chassis as well as 2023-2024 Ram 2500, 4500/5500 Cab Chassis and Ram 3500 vehicles, according to the recall notice from the National Highway Traffic Safety Administration. The steering column control module may cause the high beams (also known as "brights") to activate when the turn signal is used, or it may activate the turn signal when the high beams are used.

The turn signal self-canceling feature may also not function properly, according to the recall.

In total, 142,150 potential cars are affected by the recall.

Owner notification letters of the recall are expected to be mailed Jan. 17, 2024. Dealers will inspect and replace the steering column control module free of charge if it is deemed necessary.

How to learn more about the Chrysler recall

Car owners can contact FCA US LLC customer service, the company that owns Chrysler, at 1-800-853-1403. The recall number is B2A.

You can also contact the National Highway Traffic Safety Administration Vehicle Safety Hotline at 1-888-327-4236 (TTY 1-800-424-9153), or go to www.nhtsa.gov.

More recalls:See USA TODAY's database of consumer products, food, drugs and automotive recalls here.

More:Scams

Recommend

Nearly half of US teens are online ‘constantly,’ Pew report finds

Nearly half of American teenagers say they are online “constantly” despite concerns about the effect

Loyalty above all: Removal of top Chinese officials seen as enforcing Xi’s demand for obedience

TAIPEI, Taiwan (AP) — The removal of China’s foreign and defense ministers appears to enforce leader

FDA says the decongestant in your medicine cabinet probably doesn't work. Now what?

Just before cold and flu season is set to kick off, the Food and Drug Administration's advisory pane